A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

ER-Positive HER2-Negative Breast Cancer

Interventions

DRUG: Camizestrant
DRUG: Ribociclib

Sponsor

AstraZeneca

Collaborators

[object Object]